Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Communication On Missed Deadlines Can Help Avoid Drug Review Limbo

Executive Summary

Providing a new target decision date in tandem with missing a user fee review deadline would help FDA restore credibility and predictability to the review process, former FDA official Bruce Burlington suggests
Advertisement

Related Content

FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
Industry Pays Fees, FDA Should Deliver, Nissen Says Of Missed PDUFA Dates
FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
Advertisement
UsernamePublicRestriction

Register

PS050465

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel